Did some DD on 3rd Eye with those who would know. Typically a last hope lender, so they want large returns with great security and they are supposedly not shy about grabbbing the security. From what I understand, this deal would be a bit of a variation to their standard deal and would say a lot about the IP RVX has for them to do the deal, assuming it closes. But sounds like RVX better have the money to pay them off within a year.

Someone also mentioned if this closes maybe RVX would have money to move on the Phase 2 Kidney and Fabry, but based on the significant liabilies on the last balance sheet, I would suggest this money on its own at best takes RVX to the top line data annoucement or so. Any other addtional raise would maybe allow them to move on phase 2 testing. My best guess.